Market Research Logo

Nymox Pharmaceutical Corporation - Product Pipeline Review - 2015

Nymox Pharmaceutical Corporation - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Nymox Pharmaceutical Corporation - Product Pipeline Review - 2015’, provides an overview of the Nymox Pharmaceutical Corporation’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Nymox Pharmaceutical Corporation’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Nymox Pharmaceutical Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Nymox Pharmaceutical Corporation’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Nymox Pharmaceutical Corporation’s pipeline products
Reasons to buy
  • Evaluate Nymox Pharmaceutical Corporation’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Nymox Pharmaceutical Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Nymox Pharmaceutical Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Nymox Pharmaceutical Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Nymox Pharmaceutical Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Nymox Pharmaceutical Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues


Nymox Pharmaceutical Corporation Snapshot
Nymox Pharmaceutical Corporation Overview
Key Information
Key Facts
Nymox Pharmaceutical Corporation - Research and Development Overview
Key Therapeutic Areas
Nymox Pharmaceutical Corporation - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Nymox Pharmaceutical Corporation - Pipeline Products Glance
Nymox Pharmaceutical Corporation - Late Stage Pipeline Products
Phase III Products/Combination Treatment Modalities
Nymox Pharmaceutical Corporation - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Nymox Pharmaceutical Corporation - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Nymox Pharmaceutical Corporation - Drug Profiles
NX-1207
Product Description
Mechanism of Action
R&D Progress
NXB-4221
Product Description
Mechanism of Action
R&D Progress
NXC-4720
Product Description
Mechanism of Action
R&D Progress
NXB-5886
Product Description
Mechanism of Action
R&D Progress
NXT-1021
Product Description
Mechanism of Action
R&D Progress
Nymox Pharmaceutical Corporation - Pipeline Analysis
Nymox Pharmaceutical Corporation - Pipeline Products by Route of Administration
Nymox Pharmaceutical Corporation - Pipeline Products by Molecule Type
Nymox Pharmaceutical Corporation - Recent Pipeline Updates
Nymox Pharmaceutical Corporation - Dormant Projects
Nymox Pharmaceutical Corporation - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
NX-1207
Nymox Pharmaceutical Corporation - Company Statement
Nymox Pharmaceutical Corporation - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Nymox Pharmaceutical Corporation, Key Information
Nymox Pharmaceutical Corporation, Key Facts
Nymox Pharmaceutical Corporation - Pipeline by Indication, 2015
Nymox Pharmaceutical Corporation - Pipeline by Stage of Development, 2015
Nymox Pharmaceutical Corporation - Monotherapy Products in Pipeline, 2015
Nymox Pharmaceutical Corporation - Phase III, 2015
Nymox Pharmaceutical Corporation - Phase II, 2015
Nymox Pharmaceutical Corporation - Preclinical, 2015
Nymox Pharmaceutical Corporation - Discovery, 2015
Nymox Pharmaceutical Corporation - Pipeline by Route of Administration, 2015
Nymox Pharmaceutical Corporation - Pipeline by Molecule Type, 2015
Nymox Pharmaceutical Corporation - Recent Pipeline Updates, 2015
Nymox Pharmaceutical Corporation - Dormant Developmental Projects,2015
Nymox Pharmaceutical Corporation - Discontinued Pipeline Products, 2015
Nymox Pharmaceutical Corporation, Subsidiaries
List of Figures
Nymox Pharmaceutical Corporation - Pipeline by Top 10 Indication, 2015
Nymox Pharmaceutical Corporation - Pipeline by Stage of Development, 2015
Nymox Pharmaceutical Corporation - Monotherapy Products in Pipeline, 2015
Nymox Pharmaceutical Corporation - Pipeline by Top 10 Route of Administration, 2015
Nymox Pharmaceutical Corporation - Pipeline by Top 10 Molecule Type, 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report